Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice.

Cheung WW, Ding W, Gunta SS, Gu Y, Tabakman R, Klapper LN, Gertler A, Mak RH.

J Am Soc Nephrol. 2014 Jan;25(1):119-28. doi: 10.1681/ASN.2013040432. Epub 2013 Oct 10.

2.

The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice.

Quaglino E, Mastini C, Iezzi M, Forni G, Musiani P, Klapper LN, Hardy B, Cavallo F.

Vaccine. 2005 May 9;23(25):3280-7.

PMID:
15837233
3.

Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library.

Vaisman N, Nissim A, Klapper LN, Tirosh B, Yarden Y, Sela M.

Immunol Lett. 2000 Dec 1;75(1):61-7.

PMID:
11163868
4.

Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies.

Hurwitz E, Klapper LN, Wilchek M, Yarden Y, Sela M.

Cancer Immunol Immunother. 2000 Jul;49(4-5):226-34.

PMID:
10941905
5.

c-Cbl is a suppressor of the neu oncogene.

Levkowitz G, Oved S, Klapper LN, Harari D, Lavi S, Sela M, Yarden Y.

J Biol Chem. 2000 Nov 10;275(45):35532-9.

6.

Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.

Klapper LN, Waterman H, Sela M, Yarden Y.

Cancer Res. 2000 Jul 1;60(13):3384-8.

7.

Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

Klapper LN, Kirschbaum MH, Sela M, Yarden Y.

Adv Cancer Res. 2000;77:25-79. Review.

PMID:
10549355
8.

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y.

Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4995-5000.

9.

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.

Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y.

EMBO J. 1998 Jun 15;17(12):3385-97.

10.

The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.

Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y.

Oncogene. 1998 Mar 12;16(10):1249-58.

11.

Bivalence of EGF-like ligands drives the ErbB signaling network.

Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y.

EMBO J. 1997 Aug 15;16(16):4938-50.

12.

A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.

Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M.

Oncogene. 1997 May 1;14(17):2099-109.

13.

Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins.

Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y.

Oncogene. 1996 Mar 7;12(5):1117-25.

PMID:
8649804

Supplemental Content

Loading ...
Support Center